Implandata Ophthalmic Products GmbH (Implandata) is a disruptive ophthalmic digital health company, located in Hannover, Germany.
With its CE marked EYEMATE™ system for remote monitoring and care of glaucoma patients, Implandata is going to transform the treatment of glaucoma. With 80 million patients at risk of permanent loss of eyesight due to glaucoma, Implandata is addressing an underserved medical need in a vast and further growing market. Implandata’s EYEMATE™ system enables eye care specialists to remotely manage their patients and personalize treatment in order to preserve glaucoma patients’ eyesight. Glaucoma patients are empowered via self-monitoring, resulting in improved therapy compliance and quality of life.
Initial investment:
2010
B2G Partner:
Günter Steffen
Milestones
Milestones
“B2G helped us at a decisive stage in the development of our business, with financial support and expertise, so that we were able to reach key milestones on the path toward marketing our product.”
Max Ostermeier
Founder and CEO